Celgene Corp

CELG-Q

NASDAQ:CELG

108.24
0.00 (0.00%)
Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey.
More at Wikipedia

Analysis and Opinions about CELG-Q

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
January 17, 2020

(A Top Pick Dec 03/18, Up 47%) Celgene had made a number of mis-steps, including management applying for multiple FDA approvals. One thing he really liked about the acquisition was the price it was bought. The acquisition by BMY helped them diversify and it seems to be going well.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
January 17, 2020

(A Top Pick Dec 03/18, Up 47%) Celgene had made a number of mis-steps, including management applying for multiple FDA approvals. One thing he really liked about the acquisition was the price it was bought. The acquisition by BMY helped them diversify and it seems to be going well.

SELL
SELL
November 27, 2019
He sold out because it's going to be merged with Bristol Myers, they received full value, and there's always deal risk. Celgene owners may get a premium if 3 drugs come to market and exceeded certain thresholds. This is a side bet, and not the way he likes to invest.
Show full opinionHide full opinion
Celgene Corp (CELG-Q)
November 27, 2019
He sold out because it's going to be merged with Bristol Myers, they received full value, and there's always deal risk. Celgene owners may get a premium if 3 drugs come to market and exceeded certain thresholds. This is a side bet, and not the way he likes to invest.
PAST TOP PICK
PAST TOP PICK
October 16, 2019

(A Top Pick Oct 22/18, Up 25%) The Bristol acquisition was perfect. CELG boasts strong competitive barriers to their products and their product pipeline will pleasantly surprise the market. He's not worried about the US election and the negative effect on US healthcare; in fact, he loves buying stocks when others fear or hate them.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
October 16, 2019

(A Top Pick Oct 22/18, Up 25%) The Bristol acquisition was perfect. CELG boasts strong competitive barriers to their products and their product pipeline will pleasantly surprise the market. He's not worried about the US election and the negative effect on US healthcare; in fact, he loves buying stocks when others fear or hate them.

COMMENT
COMMENT
September 25, 2019

He started buying BMY-N ahead of the merger discussions with CELG-Q. If the merger fails, holding the buyer is safer as arbitragers unwind hedges. The combined company would be a good cash flow generator, which would help internal growth and debt pay down.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
September 25, 2019

He started buying BMY-N ahead of the merger discussions with CELG-Q. If the merger fails, holding the buyer is safer as arbitragers unwind hedges. The combined company would be a good cash flow generator, which would help internal growth and debt pay down.

John Kim

Unlock Ratings

Price
$98.560
Owned
Unknown
DON'T BUY
DON'T BUY
August 6, 2019

Heading into the election cycle, pharma will be under pressure. He prefers being into medical devices. He has a hard time being excited about either CELG or BMY, especially if the market is currently jittery. (Analysts’ price target is $100.33)

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
August 6, 2019

Heading into the election cycle, pharma will be under pressure. He prefers being into medical devices. He has a hard time being excited about either CELG or BMY, especially if the market is currently jittery. (Analysts’ price target is $100.33)

PAST TOP PICK
PAST TOP PICK
May 3, 2019
(A Top Pick Mar 21/18, Up 10%) Sold it because it's getting taken out by Bristol Myers.
Show full opinionHide full opinion
(A Top Pick Mar 21/18, Up 10%) Sold it because it's getting taken out by Bristol Myers.
BUY
BUY
April 22, 2019
Bistol-Myers bought it which is good news for Celgene holders.
Show full opinionHide full opinion
Celgene Corp (CELG-Q)
April 22, 2019
Bistol-Myers bought it which is good news for Celgene holders.
PAST TOP PICK
PAST TOP PICK
April 8, 2019
(A Top Pick May 30/18, Up 22%) They have a lot of new products in their patent portfolio. They are being acquired. It would be a nice speculative holding in the marketplace when it closes.
Show full opinionHide full opinion
Celgene Corp (CELG-Q)
April 8, 2019
(A Top Pick May 30/18, Up 22%) They have a lot of new products in their patent portfolio. They are being acquired. It would be a nice speculative holding in the marketplace when it closes.
PAST TOP PICK
PAST TOP PICK
February 11, 2019
(A Top Pick Mar 20/18, Down 0.2%) It was one of his hopes in the medical area for great growth. They are being acquired. He is going to keep holding it.
Show full opinionHide full opinion
Celgene Corp (CELG-Q)
February 11, 2019
(A Top Pick Mar 20/18, Down 0.2%) It was one of his hopes in the medical area for great growth. They are being acquired. He is going to keep holding it.
SELL
SELL
January 10, 2019
Having issues in terms of competition. They wanted to merge with Bristol. She doesn't think the combination makes it a better company. She would sell on the announcement (as the stock lifted).
Show full opinionHide full opinion
Celgene Corp (CELG-Q)
January 10, 2019
Having issues in terms of competition. They wanted to merge with Bristol. She doesn't think the combination makes it a better company. She would sell on the announcement (as the stock lifted).
BUY
BUY
December 31, 2018
It has a better growth pipeline. Biotech in the US is probably one of the better areas of growth. He prefers the IBB-Q ETF. He likes the sector. There is good growth potential.
Show full opinionHide full opinion
Celgene Corp (CELG-Q)
December 31, 2018
It has a better growth pipeline. Biotech in the US is probably one of the better areas of growth. He prefers the IBB-Q ETF. He likes the sector. There is good growth potential.
TOP PICK
TOP PICK
December 3, 2018
They're in oncology, particularly blood cancer. They've had some headwinds in some FDA submissions due to mistakes by management. So, the stock got punished. It's trading at 6.5x and generating a ton of cash flow as good test results come in. They are diversifying as they acquire. Hoeps investor sentiment improves. (Analysts’ price target is $108.61)
Show full opinionHide full opinion
Celgene Corp (CELG-Q)
December 3, 2018
They're in oncology, particularly blood cancer. They've had some headwinds in some FDA submissions due to mistakes by management. So, the stock got punished. It's trading at 6.5x and generating a ton of cash flow as good test results come in. They are diversifying as they acquire. Hoeps investor sentiment improves. (Analysts’ price target is $108.61)
DON'T BUY
DON'T BUY
November 12, 2018
They have drugs going off patent in 2020. They have 5 big names coming into trials at the same time. He is not clear on what will cause it to bounce. Don't buy lows. The price is confirmed by relative strength.
Show full opinionHide full opinion
Celgene Corp (CELG-Q)
November 12, 2018
They have drugs going off patent in 2020. They have 5 big names coming into trials at the same time. He is not clear on what will cause it to bounce. Don't buy lows. The price is confirmed by relative strength.
TOP PICK
TOP PICK
October 22, 2018

(no dividend yield, Analysts' price target: not given) A global biotech focussed on cancer. They've stumbled recently, but phase 3 trials have been positive. Their drugs have a diminished chance of going generic, according to data. Attractive value. smart managers and a rich pipeline of drugs coming.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
October 22, 2018

(no dividend yield, Analysts' price target: not given) A global biotech focussed on cancer. They've stumbled recently, but phase 3 trials have been positive. Their drugs have a diminished chance of going generic, according to data. Attractive value. smart managers and a rich pipeline of drugs coming.

DON'T BUY
DON'T BUY
October 10, 2018

They have a good cash float, which will lead to a share buyback, he feels. He sees resistance at $90-$100, which will be tough to battle through. He would suggest taking a loss if you hold this one, because the future capex requirements will be more expensive as interest rates rise. He would prefer IHI-N if you like the healthcare space as he does.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
October 10, 2018

They have a good cash float, which will lead to a share buyback, he feels. He sees resistance at $90-$100, which will be tough to battle through. He would suggest taking a loss if you hold this one, because the future capex requirements will be more expensive as interest rates rise. He would prefer IHI-N if you like the healthcare space as he does.

Showing 1 to 15 of 90 entries

Celgene Corp(CELG-Q) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 5

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 7

Stockchase rating for Celgene Corp is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Celgene Corp(CELG-Q) Frequently Asked Questions

What is Celgene Corp stock symbol?

Celgene Corp is a American stock, trading under the symbol CELG-Q on the NASDAQ (CELG). It is usually referred to as NASDAQ:CELG or CELG-Q

Is Celgene Corp a buy or a sell?

In the last year, 7 stock analysts published opinions about CELG-Q. 5 analysts recommended to BUY the stock. 2 analyst recommended to SELL the stock. The latest stock analyst recommendation is PAST TOP PICK. Read the latest stock experts' ratings for Celgene Corp.

Is Celgene Corp a good investment or a top pick?

Celgene Corp was recommended as a Top Pick by Paul MacDonald on 2020-01-17. Read the latest stock experts ratings for Celgene Corp.

Why is Celgene Corp stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Celgene Corp worth watching?

7 stock analysts on Stockchase covered Celgene Corp In the last year. It is a trending stock that is worth watching.

What is Celgene Corp stock price?

On 2019-11-20, Celgene Corp (CELG-Q) stock closed at a price of $108.24.